Who can enter
- Children and young adults with metastatic newly diagnosed Ewing sarcoma
- Age: 2 until 50 years old; in the Netherlands, only children and young adults treated at the Princess Máxima Center can participate. In other countries, older patients up to 50 years old can participate.
Goal
The goal of this study is to determine the optimal dose of the drug regorafenib when taken alongside the standard treatment regimen.
Background
Patients with Ewing sarcoma are treated with courses of chemotherapy. Several drugs are given during the courses of chemotherapy. Regorafenib is a new drug that inhibits cancer cells. We want to give this drug in addition to the standard courses, but the optimal dose is not yet known.
In this study, we want to determine what the best dose is when we give regorafenib alongside standard chemotherapy courses. We are testing different doses for this purpose. We are also looking at side effects and efficacy.
Regorafenib can be taken at home. It can be taken in tablet form and as granules. The drug is approved for adults in the Netherlands. It has also been given to children in smaller studies.